• Biotechnology company Schlieren | Zürich

About us

Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation. The firm’s strength is rooted in extensive and successful experiences in both the pharmaceutical and biotech industry, along with a solid academic track record.

Rationale

Human-derived antibodies have superior therapeutic potential compared to antibodies derived from conventional sources, such as humanized animal models or artificial libraries. In addition, they offer unique opportunities to learn about the target’s human biology. In the case of allergy, for instance, antibodies derived from allergic patients target disease-relevant epitopes, expanding our knowledge of allergenic epitopes at a molecular level and their significance in the context of the disease.

Technology

The fully human antibodies are identified and rapidly cloned using B-cell screening technologies and antibody-expression platforms. Within two to three weeks, B cell screening hits are cloned and expressed as monoclonal antibodies. The speed and versatility, as well as the subsequent downstream focus on functional assays to select best-in-class antibodies are at the heart of Mabylon’s discovery platform.